American Indian/Alaska Native men are less likely to receive prostate-specific antigen testing and digital rectal exams from primary care providers than White men: a secondary analysis of the National Ambulatory Medical Care Survey from 2012–2018

Author:

Gillette Chris,Locklear Tony,Bell Ronny,Bates Nathan,Ostermann Jan,Reuland Daniel,Foley Kristie,Lashmit Cheyenne,Crandall Sonia

Abstract

Abstract Purpose (1) Identify the proportion of primary care visits in which American Indian/Alaska Native (AI/AN) men receive a prostate-specific antigen test (PSAT)and/or a digital rectal exam (DRE), (2) describe characteristics of primary care visits in which AI/AN receive PSA and/or DRE, and (3) identify whether AI/AN receive PSA and/or DRE less often than non-Hispanic White (nHW) men. Methods This was a secondary analysis of the National Ambulatory Medical Care Survey (NAMCS) during 2013–2016 and 2018 and the NAMCS Community Health Center (CHC) datasets from 2012–2015. Weighted bivariate and multivariable tests analyzed the data to account for the complex survey design. Results For AI/AN men, 1.67 per 100 visits (95% CI = 0–4.24) included a PSATs (or PSAT) and 0 visits included a DRE between 2013–2016 and 2018. The rate of PSA for non-AI/AN men was 9.35 per 100 visits (95% CI = 7.78–10.91) and 2.52 per 100 visits (95% CI = 1.61–3.42) for DRE. AI/AN men were significantly less likely to receive a PSA than nHW men (aOR = 0.09, 95% CI = 0.01–0.83). In CHCs, AI/AN men experienced 4.26 PSAT per 100 visits (95% CI = 0.96–7.57) compared to 5.00 PSAT per 100 visits (95% CI = 4.40–5.68) for non-AI/AN men. DRE rates for AI/AN men was 0.63 per 100 visits (95% CI = 0–1.61) compared to 1.05 per 100 (95% CI = 0.74–1.37) for non-AI/AN men. There was not a statistically significant disparity in the CHC data regarding PSA (OR = 0.91, 95% CI = 0.42–1.98) or DRE (OR = 0.75, 95% CI = 0.15–3.74), compared to nHW men. Conclusion Efforts are needed to better understand why providers may not use PSA and DRE with AI/AN men compared to nHW men.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3